



Versameb CEO Klaas Zuideveld to Present at the RNA Leaders World Congress

Presentation demonstrates lead therapeutic candidate VMB-100 has the potential to address the unmet medical needs of patients suffering from Stress Urinary Incontinence

10 March 2022, Basel, Switzerland: Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its leadership team will be attending the [RNA Leaders World Congress](#), taking place on the 16-17th March 2022 in Basel, Switzerland, where Chief Executive Officer Klaas Zuideveld will be presenting data on the Company’s mRNA engineering technology and its lead therapeutic candidate, VMB-100.

Versameb has developed a groundbreaking, proprietary technology platform which optimizes the application of functional RNA in different disease contexts. Its lead therapeutic candidate VMB-100 has demonstrated first-in-class potential for treatment for Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter.

[RNA Leaders World Congress](#)

Date: 16-17 March 2022, Congress Center, Basel, Switzerland

Presentation by: Klaas Zuideveld, Chief Executive Officer, Versameb

Title: Regeneration of urethral muscle in Stress Urinary Incontinence using engineered mRNA

Date & Time: Wednesday, 16th March 2022, 12.00pm CET

Klaas Zuideveld, Chief Executive Officer, said: “We are delighted to be presenting data on our proprietary platform and lead asset at the RNA Leaders World Congress on the 16th of March 2022. Our next generation RNA platform has demonstrated pioneering potential for mRNA-based therapeutics in Stress Urinary Incontinence and other indications. We are committed and working towards bringing our innovative technology to patients suffering from SUI, an unmet medical need with no drug treatment approved for restoration.”

Our understanding of RNA biology continues to mature. With that in mind, the first annual RNA Leaders World Congress brings together more than 150 biotech, pharmaceutical, investment, regulatory and scientific professionals at the RNA Leaders World Congress. Topics include the latest advances in RNA biology, updates from the companies developing new therapies and services partners who are helping to deliver drugs to patients. Versameb are bronze sponsors of the Congress.

If you would like to meet with the Versameb team at the above event, please contact us at the details provided below. For more information, please visit us at <https://versameb.com/upcoming-conferences-events/>

-Ends-



Contact for media enquiries:

Versameb

Dr Klaas Zuideveld, CEO

Ir@versameb.com

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Zoe Bolt

Tel: +44 (0)20 3882 9621

versameb@optimumcomms.com

About Versameb

Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting. Based in Basel and fully operational from 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient. Versameb's proprietary technology platform, VERSagile, optimizes the application of functional RNA in different disease contexts – making RNA druggable in new therapeutic areas others have been unable to solve. The pipeline includes lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors. Versameb is working towards the completion of a first in-human/proof-of-concept clinical study while advancing its platform. More information on Versameb can be found at www.versameb.com as well as on [LinkedIn](#).

About Stress Urinary Incontinence (SUI)

Versameb's lead molecule is currently undergoing advanced preclinical development activities for the treatment of stress urinary incontinence. A significant acceleration of functional recovery and tissue regeneration has been observed after different types of injuries in preclinical models, showing its regenerative potential. With the lead molecule moving towards clinic and the advance of additional assets in therapeutic areas of high unmet medical need, Versameb is creating an attractive and balanced portfolio. For more information and resources on stress urinary incontinence, please see Versameb's [SUI fact sheet](#).

About RNA Leaders World Congress

RNA Leaders World Congress provides latest advances in RNA chemistry and clinical updates from the companies developing new therapies and sources the service partners who are helping to deliver drugs to patients. <https://www.lsxleaders.com/rna-leaders-world-congress>.